CO2023014322A2 - Terapias de combinación - Google Patents

Terapias de combinación

Info

Publication number
CO2023014322A2
CO2023014322A2 CONC2023/0014322A CO2023014322A CO2023014322A2 CO 2023014322 A2 CO2023014322 A2 CO 2023014322A2 CO 2023014322 A CO2023014322 A CO 2023014322A CO 2023014322 A2 CO2023014322 A2 CO 2023014322A2
Authority
CO
Colombia
Prior art keywords
effective amount
combinations
formula
combination therapies
therapeutically effective
Prior art date
Application number
CONC2023/0014322A
Other languages
English (en)
Spanish (es)
Inventor
Vineet Pande
Wei Cai
Xuedong Dai
Olivier Alexis Georges Querolle
Yingtao Liu
Lianzhu Liu
Yanping Xu
Liqiang Fu
Ming Li
Lichao Fang
Xiangjun Deng
Alicia Tee Fuay Ng
Nicolas Freddy J Darville
Nikki Daskalakis
Christina Diane Guttke
Min Chul Kwon
Lucille Angela Ferrante
Kathryn Elizabeth Packman
Eva Christine Pietsch
Ulrike Philippar
Tinne Ann J Verhulst
Balpreet Bhogal
Yu Sun
Johannes Wilhelmus J Thuring
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2023014322A2 publication Critical patent/CO2023014322A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0014322A 2021-05-11 2023-10-25 Terapias de combinación CO2023014322A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CN2021100523 2021-06-17
CN2022086004 2022-04-11
PCT/CN2022/091679 WO2022237720A1 (en) 2021-05-11 2022-05-09 Combination therapies

Publications (1)

Publication Number Publication Date
CO2023014322A2 true CO2023014322A2 (es) 2023-11-20

Family

ID=81753154

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0014322A CO2023014322A2 (es) 2021-05-11 2023-10-25 Terapias de combinación

Country Status (16)

Country Link
EP (1) EP4337216A1 (https=)
JP (1) JP2024518497A (https=)
KR (1) KR20240006631A (https=)
CN (2) CN117460513A (https=)
AU (1) AU2022274071A1 (https=)
CA (1) CA3215313A1 (https=)
CL (2) CL2023003239A1 (https=)
CO (1) CO2023014322A2 (https=)
DO (1) DOP2023000246A (https=)
IL (1) IL308335A (https=)
MX (1) MX2023013410A (https=)
PE (1) PE20240593A1 (https=)
PH (1) PH12023552974A1 (https=)
TW (1) TW202308643A (https=)
UY (1) UY39761A (https=)
WO (1) WO2022237720A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4698182A1 (en) * 2023-04-17 2026-02-25 Janssen Pharmaceutica NV Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder
WO2025082444A2 (en) * 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000080A1 (en) 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
WO2017214367A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Also Published As

Publication number Publication date
AU2022274071A1 (en) 2024-01-04
MX2023013410A (es) 2023-12-06
JP2024518497A (ja) 2024-05-01
DOP2023000246A (es) 2024-04-30
IL308335A (en) 2024-01-01
CL2024002832A1 (es) 2025-02-14
CA3215313A1 (en) 2022-11-17
PH12023552974A1 (en) 2024-03-11
CL2023003239A1 (es) 2024-06-07
PE20240593A1 (es) 2024-03-21
TW202308643A (zh) 2023-03-01
CN118845787A (zh) 2024-10-29
UY39761A (es) 2022-11-30
CN117460513A (zh) 2024-01-26
EP4337216A1 (en) 2024-03-20
WO2022237720A1 (en) 2022-11-17
KR20240006631A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
CO2023014322A2 (es) Terapias de combinación
MX2021005898A (es) Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
UY38160A (es) Partículas implantables y métodos relacionados
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
BR112022010377A2 (pt) Novos tiromiméticos
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
DOP2023000239A (es) Terapias de combinacion
MX2012001654A (es) Metodos para usar moduladores de c-met.
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
CO2021008816A2 (es) Moduladores de trex1
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CO2022000266A2 (es) Inhibidores de enzimas
MX2024005670A (es) Analogos deuterados de acetil-leucina.
MX2023010506A (es) Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.
MX2020011367A (es) Compuesto oxo-sustituido.
MX2019004872A (es) Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer.
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
CL2023003168A1 (es) Moduladores de trex1
CL2021002144A1 (es) Compuesto heterociclo pentacíclico.
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
MX2022002000A (es) Derivados de pirazol y uso de los mismos.